Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reckitt Expands 'OTC' Business, China Presence With Mead Johnson

Executive Summary

Marketing Enfamil and other Mead Johnson formula and nutritional brands, says RB CEO Rakesh Kapoor, is "very much in the core of what consumer health stands for," and also immediately doubles the size of the firm's consumer business.


Related Content

Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?
RB Says Petya Cyberattack Froze Shipments, Could Cost £100M
RB Says Petya Cyberattack Froze Shipments, Could Cost £100M
MJ, RB Shareholders Approve Deal: Health & Wellness News Roundup
Biopharma Quarterly Deal-Making Statistics, Q1 2017
RB Eyes MJN, Spiked Supplements, GMP Warning: Health & Wellness Industry News Roundup
Industry Roundup: SEC Fines MJN, Criminal Charge For Herbals Seller, Decree Closes Aspen Supplement Marketer
China Tightens Infant Formula Industry Oversight, Levels Playing Field
Reckitt Consumer Health Growth Helps Fuel Pharma Unit Divestment Buzz
Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts